Blood-Based Test Developed for Diagnosing Alzheimer's Disease
By LabMedica International staff writers Posted on 23 Mar 2015 |
Image: Histopathology of cerebral diffuse beta amyloid plaque (Photo courtesy of Dr. Dimitri P. Agamanolis, MD).
A simple blood test has been developed to confirm the presence of beta amyloid proteins in the brain, which is a hallmark of Alzheimer's disease (AD), and could be a key advance in diagnosing this neurodegenerative disorder.
Blood-based biomarkers for AD would have the important advantage of being safe, affordable, and easy to administer in large cohorts and/or in rural areas and therefore could have an enormous impact on clinical care and clinical trials alike.
A team of scientists led by those at the David Geffen School of Medicine at University of California (Los Angeles, CA, USA) developed a multimodal biomarker classifier for predicting brain amyloidosis using cognitive, imaging, and peripheral blood protein from the Alzheimer's Disease Neuroimaging Initiative 1 (ADNI1) mild cognitive impairment (MCI) cohort data. ADNI1 enrolled 398 subjects with MCI. The 151 subjects with MCI provided peripheral blood and CSF, but not Pittsburgh compound B-positron emission tomography (PiB-PET) data, were selected for inclusion in the training sample. Conversely, the 60 subjects with MCI who provided peripheral blood and PiB-PET imaging constituted the testing sample.
Apolipoprotein E (ApoE) genotyping was performed for all study participants using anti-coagulated blood samples. Quantitative polymerase chain reaction assays were used for genotyping ApoE nucleotides 334 T/C (rs 429358) and 472 C/T (rs 7412) with the ABI 7900 real-time thermocycler (Applied Biosystems; Foster City, CA, USA) using DNA freshly prepared from ethylenediaminetetraacetic acid (EDTA) treated whole blood. The team selected relevant peripheral blood proteins for inclusion in their model, ones where demonstrable aberrant levels of each of these proteins in peripheral blood in AD have found associations between their concentrations and subsequent cognitive decline and/or imaging change.
The results of the study suggest that plasma, imaging, and cognitive measures can be used to potentially predict brain amyloidosis with modest accuracy and confirm the AD relevance of interleukin 6 receptor (IL-6R) and clusterin, the two plasma measures that proved useful for this classification. For identification of subjects with MCI at greatest risk of disease progression to dementia, the self-tuning classifiers achieved reasonable but modest predictive accuracy.
Liana G. Apostolova, MD, MSc, the lead author of the study said, “Our study suggests that blood protein panels can be used to establish the presence of Alzheimer's-type pathology of the brain in a safe and minimally invasive manner. We need to further refine and improve on the power of this signature by introducing new disease-related metrics, but this indicates that such a test is feasible and could be on the market before long.” The study was published on February 17, 2015, in the journal Neurology.
Related Links:
David Geffen School of Medicine
Applied Biosystems
Blood-based biomarkers for AD would have the important advantage of being safe, affordable, and easy to administer in large cohorts and/or in rural areas and therefore could have an enormous impact on clinical care and clinical trials alike.
A team of scientists led by those at the David Geffen School of Medicine at University of California (Los Angeles, CA, USA) developed a multimodal biomarker classifier for predicting brain amyloidosis using cognitive, imaging, and peripheral blood protein from the Alzheimer's Disease Neuroimaging Initiative 1 (ADNI1) mild cognitive impairment (MCI) cohort data. ADNI1 enrolled 398 subjects with MCI. The 151 subjects with MCI provided peripheral blood and CSF, but not Pittsburgh compound B-positron emission tomography (PiB-PET) data, were selected for inclusion in the training sample. Conversely, the 60 subjects with MCI who provided peripheral blood and PiB-PET imaging constituted the testing sample.
Apolipoprotein E (ApoE) genotyping was performed for all study participants using anti-coagulated blood samples. Quantitative polymerase chain reaction assays were used for genotyping ApoE nucleotides 334 T/C (rs 429358) and 472 C/T (rs 7412) with the ABI 7900 real-time thermocycler (Applied Biosystems; Foster City, CA, USA) using DNA freshly prepared from ethylenediaminetetraacetic acid (EDTA) treated whole blood. The team selected relevant peripheral blood proteins for inclusion in their model, ones where demonstrable aberrant levels of each of these proteins in peripheral blood in AD have found associations between their concentrations and subsequent cognitive decline and/or imaging change.
The results of the study suggest that plasma, imaging, and cognitive measures can be used to potentially predict brain amyloidosis with modest accuracy and confirm the AD relevance of interleukin 6 receptor (IL-6R) and clusterin, the two plasma measures that proved useful for this classification. For identification of subjects with MCI at greatest risk of disease progression to dementia, the self-tuning classifiers achieved reasonable but modest predictive accuracy.
Liana G. Apostolova, MD, MSc, the lead author of the study said, “Our study suggests that blood protein panels can be used to establish the presence of Alzheimer's-type pathology of the brain in a safe and minimally invasive manner. We need to further refine and improve on the power of this signature by introducing new disease-related metrics, but this indicates that such a test is feasible and could be on the market before long.” The study was published on February 17, 2015, in the journal Neurology.
Related Links:
David Geffen School of Medicine
Applied Biosystems
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans